GPT and Cirrhosis: The study found a significant benefit from treatment both in those at high risk of HCC development such as male gender, older age, cirrhosis, and high REACH-B scores, but also in patients defined as low risk as female gender, younger age, lack of cirrhosis, HBeAg negative, normal to minimally elevated ALT levels, and low-to-middle REACH-B scores (<14) [158].